Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teverelix DP in advanced prostate cancer
NCT07457164Phase 2Not yet recruiting
- Sponsor
- Antev
- Start
- Jul 2026
- Primary completion
- Sep 2027
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 2 trial of teverelix in prostate cancer (PCa), sponsored by Antev. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
teverelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07457164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07457164.